Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | yes | yes: 25 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 16 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 7 |
NetGPI | no | yes: 0, no: 7 |
Related structures:
AlphaFold database: Q4QI38
Term | Name | Level | Count |
---|---|---|---|
GO:0000052 | citrulline metabolic process | 5 | 3 |
GO:0006082 | organic acid metabolic process | 3 | 3 |
GO:0006520 | amino acid metabolic process | 3 | 3 |
GO:0006525 | arginine metabolic process | 6 | 3 |
GO:0006807 | nitrogen compound metabolic process | 2 | 3 |
GO:0008152 | metabolic process | 1 | 3 |
GO:0009064 | glutamine family amino acid metabolic process | 5 | 3 |
GO:0009889 | regulation of biosynthetic process | 4 | 3 |
GO:0009891 | positive regulation of biosynthetic process | 5 | 3 |
GO:0009893 | positive regulation of metabolic process | 4 | 3 |
GO:0009987 | cellular process | 1 | 3 |
GO:0019222 | regulation of metabolic process | 3 | 3 |
GO:0019752 | carboxylic acid metabolic process | 5 | 3 |
GO:0031323 | regulation of cellular metabolic process | 4 | 3 |
GO:0031325 | positive regulation of cellular metabolic process | 5 | 3 |
GO:0031326 | regulation of cellular biosynthetic process | 5 | 3 |
GO:0031328 | positive regulation of cellular biosynthetic process | 6 | 3 |
GO:0043436 | oxoacid metabolic process | 4 | 3 |
GO:0044237 | cellular metabolic process | 2 | 3 |
GO:0044238 | primary metabolic process | 2 | 3 |
GO:0044281 | small molecule metabolic process | 2 | 3 |
GO:0045428 | regulation of nitric oxide biosynthetic process | 6 | 3 |
GO:0045429 | positive regulation of nitric oxide biosynthetic process | 7 | 3 |
GO:0048518 | positive regulation of biological process | 3 | 3 |
GO:0048522 | positive regulation of cellular process | 4 | 3 |
GO:0050789 | regulation of biological process | 2 | 3 |
GO:0050794 | regulation of cellular process | 3 | 3 |
GO:0051171 | regulation of nitrogen compound metabolic process | 4 | 3 |
GO:0051173 | positive regulation of nitrogen compound metabolic process | 5 | 3 |
GO:0065007 | biological regulation | 1 | 3 |
GO:0071704 | organic substance metabolic process | 2 | 3 |
GO:0080164 | regulation of nitric oxide metabolic process | 5 | 3 |
GO:1901564 | organonitrogen compound metabolic process | 3 | 3 |
GO:1901605 | alpha-amino acid metabolic process | 4 | 3 |
GO:1904407 | positive regulation of nitric oxide metabolic process | 6 | 3 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 8 |
GO:0005488 | binding | 1 | 3 |
GO:0016403 | dimethylargininase activity | 5 | 8 |
GO:0016597 | amino acid binding | 4 | 3 |
GO:0016787 | hydrolase activity | 2 | 8 |
GO:0016810 | hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds | 3 | 8 |
GO:0016813 | hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amidines | 4 | 8 |
GO:0036094 | small molecule binding | 2 | 3 |
GO:0043177 | organic acid binding | 3 | 3 |
GO:0016740 | transferase activity | 2 | 2 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 66 | 70 | PF00656 | 0.343 |
CLV_NRD_NRD_1 | 35 | 37 | PF00675 | 0.429 |
CLV_NRD_NRD_1 | 94 | 96 | PF00675 | 0.446 |
CLV_PCSK_KEX2_1 | 94 | 96 | PF00082 | 0.446 |
CLV_PCSK_SKI1_1 | 133 | 137 | PF00082 | 0.336 |
CLV_PCSK_SKI1_1 | 200 | 204 | PF00082 | 0.430 |
CLV_PCSK_SKI1_1 | 240 | 244 | PF00082 | 0.313 |
DOC_CDC14_PxL_1 | 58 | 66 | PF14671 | 0.371 |
DOC_MAPK_gen_1 | 36 | 45 | PF00069 | 0.395 |
DOC_USP7_MATH_1 | 10 | 14 | PF00917 | 0.370 |
DOC_USP7_MATH_1 | 272 | 276 | PF00917 | 0.384 |
LIG_14-3-3_CanoR_1 | 230 | 239 | PF00244 | 0.411 |
LIG_14-3-3_CanoR_1 | 27 | 33 | PF00244 | 0.433 |
LIG_Actin_WH2_2 | 159 | 176 | PF00022 | 0.396 |
LIG_APCC_ABBA_1 | 43 | 48 | PF00400 | 0.397 |
LIG_BRCT_BRCA1_1 | 198 | 202 | PF00533 | 0.422 |
LIG_deltaCOP1_diTrp_1 | 190 | 197 | PF00928 | 0.341 |
LIG_FHA_1 | 17 | 23 | PF00498 | 0.385 |
LIG_FHA_1 | 182 | 188 | PF00498 | 0.355 |
LIG_FHA_1 | 257 | 263 | PF00498 | 0.486 |
LIG_FHA_1 | 27 | 33 | PF00498 | 0.433 |
LIG_FHA_1 | 80 | 86 | PF00498 | 0.513 |
LIG_FHA_2 | 21 | 27 | PF00498 | 0.384 |
LIG_FHA_2 | 232 | 238 | PF00498 | 0.406 |
LIG_LIR_Gen_1 | 145 | 155 | PF02991 | 0.370 |
LIG_LIR_Gen_1 | 190 | 197 | PF02991 | 0.288 |
LIG_LIR_Gen_1 | 41 | 50 | PF02991 | 0.361 |
LIG_LIR_Nem_3 | 132 | 137 | PF02991 | 0.395 |
LIG_LIR_Nem_3 | 190 | 194 | PF02991 | 0.399 |
LIG_LIR_Nem_3 | 199 | 205 | PF02991 | 0.444 |
LIG_LIR_Nem_3 | 41 | 45 | PF02991 | 0.425 |
LIG_PDZ_Class_2 | 281 | 286 | PF00595 | 0.419 |
LIG_PTB_Apo_2 | 128 | 135 | PF02174 | 0.415 |
LIG_PTB_Phospho_1 | 128 | 134 | PF10480 | 0.421 |
LIG_Rb_LxCxE_1 | 19 | 34 | PF01857 | 0.431 |
LIG_SH2_PTP2 | 134 | 137 | PF00017 | 0.382 |
LIG_SH2_PTP2 | 42 | 45 | PF00017 | 0.387 |
LIG_SH2_STAP1 | 54 | 58 | PF00017 | 0.406 |
LIG_SH2_STAT5 | 128 | 131 | PF00017 | 0.423 |
LIG_SH2_STAT5 | 134 | 137 | PF00017 | 0.387 |
LIG_SH2_STAT5 | 154 | 157 | PF00017 | 0.414 |
LIG_SH2_STAT5 | 42 | 45 | PF00017 | 0.331 |
LIG_SH3_2 | 89 | 94 | PF14604 | 0.427 |
LIG_SH3_3 | 86 | 92 | PF00018 | 0.412 |
LIG_SUMO_SIM_anti_2 | 2 | 8 | PF11976 | 0.365 |
LIG_SUMO_SIM_anti_2 | 55 | 60 | PF11976 | 0.583 |
LIG_SUMO_SIM_par_1 | 203 | 211 | PF11976 | 0.430 |
LIG_SUMO_SIM_par_1 | 28 | 34 | PF11976 | 0.417 |
LIG_TRAF2_1 | 249 | 252 | PF00917 | 0.432 |
LIG_WRC_WIRS_1 | 217 | 222 | PF05994 | 0.409 |
MOD_CK1_1 | 140 | 146 | PF00069 | 0.391 |
MOD_CK1_1 | 181 | 187 | PF00069 | 0.388 |
MOD_CK1_1 | 280 | 286 | PF00069 | 0.412 |
MOD_CK1_1 | 31 | 37 | PF00069 | 0.339 |
MOD_CK2_1 | 10 | 16 | PF00069 | 0.460 |
MOD_CK2_1 | 143 | 149 | PF00069 | 0.444 |
MOD_CK2_1 | 20 | 26 | PF00069 | 0.374 |
MOD_CK2_1 | 231 | 237 | PF00069 | 0.405 |
MOD_GlcNHglycan | 12 | 15 | PF01048 | 0.377 |
MOD_GlcNHglycan | 145 | 148 | PF01048 | 0.453 |
MOD_GlcNHglycan | 220 | 223 | PF01048 | 0.383 |
MOD_GSK3_1 | 16 | 23 | PF00069 | 0.418 |
MOD_N-GLC_1 | 143 | 148 | PF02516 | 0.419 |
MOD_N-GLC_2 | 81 | 83 | PF02516 | 0.427 |
MOD_PKA_2 | 256 | 262 | PF00069 | 0.494 |
MOD_PKA_2 | 26 | 32 | PF00069 | 0.538 |
MOD_Plk_1 | 181 | 187 | PF00069 | 0.384 |
MOD_Plk_1 | 20 | 26 | PF00069 | 0.374 |
MOD_Plk_1 | 74 | 80 | PF00069 | 0.370 |
MOD_Plk_2-3 | 117 | 123 | PF00069 | 0.359 |
MOD_Plk_2-3 | 206 | 212 | PF00069 | 0.330 |
MOD_Plk_4 | 175 | 181 | PF00069 | 0.327 |
MOD_Plk_4 | 2 | 8 | PF00069 | 0.451 |
MOD_Plk_4 | 277 | 283 | PF00069 | 0.318 |
MOD_Plk_4 | 38 | 44 | PF00069 | 0.311 |
MOD_Plk_4 | 67 | 73 | PF00069 | 0.324 |
MOD_Plk_4 | 74 | 80 | PF00069 | 0.317 |
MOD_SUMO_for_1 | 270 | 273 | PF00179 | 0.345 |
TRG_DiLeu_BaEn_1 | 182 | 187 | PF01217 | 0.387 |
TRG_ENDOCYTIC_2 | 134 | 137 | PF00928 | 0.382 |
TRG_ENDOCYTIC_2 | 148 | 151 | PF00928 | 0.429 |
TRG_ENDOCYTIC_2 | 42 | 45 | PF00928 | 0.331 |
TRG_ER_diArg_1 | 113 | 116 | PF00400 | 0.396 |
TRG_ER_diArg_1 | 94 | 96 | PF00400 | 0.446 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1I6E5 | Leptomonas seymouri | 73% | 100% |
A0A0S4J9U5 | Bodo saltans | 47% | 97% |
A0A3S7WQF2 | Leishmania donovani | 95% | 100% |
E9AG92 | Leishmania infantum | 95% | 100% |
E9AMJ6 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 90% | 100% |
O08557 | Rattus norvegicus | 29% | 100% |
O34497 | Bacillus subtilis (strain 168) | 25% | 100% |
O94760 | Homo sapiens | 28% | 100% |
P56965 | Bos taurus | 28% | 100% |
Q4QI44 | Leishmania major | 100% | 100% |
Q9CWS0 | Mus musculus | 29% | 100% |
Q9I4E3 | Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) | 31% | 100% |
Q9X7M4 | Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) | 30% | 100% |
Q9Y8N2 | Aeropyrum pernix (strain ATCC 700893 / DSM 11879 / JCM 9820 / NBRC 100138 / K1) | 32% | 100% |